Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

13.94 -0.20 (-1.41%)
Streaming Delayed Price Updated: 12:57 PM EDT, Mar 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Dr. Reddy's Laboratories Ltd Common Stock

< Previous 1 2 3 4 5 Next >
DR. Reddy's Laboratories (NYSE:RDY) Fits the Peter Lynch GARP Investment Strategy ↗
Via Chartmill
Dr. Reddy's Laboratories (NYSE:RDY) Passes Key Peter Lynch GARP Investment Test ↗
Via Chartmill
Dr. Reddy's Laboratories-ADR (NYSE:RDY) Passes Peter Lynch's GARP Investment Filter ↗
Via Chartmill
News headline image
Dr. Reddy's Laboratories (NYSE:RDY) Passes Key Peter Lynch GARP Screens ↗
Dr. Reddy's Laboratories exemplifies Peter Lynch's GARP strategy with strong earnings growth, a low PEG ratio, and a debt-free balance sheet. 
Via Chartmill
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Fits the Peter Lynch Investment Strategy ↗
Dr. Reddy's Labs fits the Peter Lynch investment model with strong EPS growth, a low PEG ratio, minimal debt, and high ROE, making it a compelling GARP stock. 
Via Chartmill
News headline image
Dr. Reddy's Laboratories (NYSE:RDY) Fits the Peter Lynch Investment Strategy ↗
Dr. Reddy's Laboratories aligns with Peter Lynch's GARP strategy, showing strong financial health, steady earnings growth, and an attractive valuation with a low PEG ratio. 
Via Chartmill
News headline image
Dr. Reddy's Laboratories-ADR (NYSE:RDY) Meets Key Peter Lynch Investment Criteria ↗
Discover Dr. Reddy's (RDY), a Peter Lynch-style GARP stock with strong earnings growth, low debt, and an attractive PEG ratio for long-term value. 
Via Chartmill
News headline image
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs ↗
The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns. 
Via Benzinga
Topics Government World Trade
News headline image
Dr. Reddy's Laboratories-ADR (NYSE:RDY) Fits the Peter Lynch GARP Strategy ↗
Dr. Reddy's Laboratories (RDY) exemplifies Peter Lynch's GARP strategy with strong 23.6% EPS growth, a low 0.80 PEG ratio, and excellent financial health. 
Via Chartmill
News headline image
Dr. Reddy's Laboratories (NYSE:RDY): A Peter Lynch-Style GARP Investment ↗
Discover how Dr. Reddy's Laboratories (RDY) exemplifies Peter Lynch's GARP investing strategy with strong earnings growth, a low PEG ratio, and a robust financial profile. 
Via Chartmill
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Fits Peter Lynch's Growth at a Reasonable Price (GARP) Strategy ↗
Dr. Reddy's Labs (RDY) fits Peter Lynch's GARP strategy with steady earnings growth, strong profitability, low debt, and fair valuation—ideal for long-term investors. 
Via Chartmill
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) – A GARP Candidate Worth Watching ↗
DR. REDDY'S LABORATORIES (NYSE:RDY) fits the GARP model with strong earnings growth, solid profitability, and a reasonable valuation, making it a candidate for long-term investors. 
Via Chartmill
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - A GARP Candidate in Pharmaceuticals ↗
DR. REDDY'S LABORATORIES (NYSE:RDY) offers strong historical growth, reasonable valuation, and solid financial health, making it a candidate for GARP investors. 
Via Chartmill
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - A GARP Candidate Worth Considering ↗
DR. REDDY'S LABORATORIES (NYSE:RDY) fits the GARP mold with strong historical growth, a low PEG ratio, and robust financials, making it a candidate for long-term investors. 
Via Chartmill
News headline image
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug ↗
Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives. 
Via Benzinga
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - A GARP Candidate Worth Considering ↗
DR. REDDY'S LABORATORIES (NYSE:RDY) offers strong earnings growth, low debt, and solid profitability, making it a candidate for GARP investors. Read why it fits the Peter Lynch strategy. 
Via Chartmill
News headline image
How does DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) stack up against Peter Lynch’s investment principles? ↗
Peter Lynch’s approach focused on identifying undervalued growth stocks with simple, scalable businesses. We examine whether DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) fits the characteristics of a... 
Via Chartmill
News headline image
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs. 
Via Benzinga
Topics Government Supply Chain World Trade
News headline image
Would Peter Lynch consider DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) a winning stock? ↗
Let’s dive into DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) using Peter Lynch’s key investing principles, from earnings growth and debt levels to long-term scalability and valuation. 
Via Chartmill
News headline image
Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business ↗
Dr. Reddy's Q3 FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion. 
Via Benzinga
News headline image
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices ↗
CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and injunctions. 
Via Benzinga
Topics Lawsuit
News headline image
Earnings Scheduled For January 23, 2025 ↗
 
Via Benzinga
News headline image
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio? ↗
The top-performing stocks last week were TEVA, KVYO, DRI, DOCS, BIRK, JBL, NBIX, GME, RDY, and LI. Did you have any of them in your portfolio? 
Via Benzinga
News headline image
Dr. Reddy's Lab Delivers 'Another Good Quarter,' CEO Says As Revenue Jumps 17% ↗
Dr. Reddy's Q2 2025 report shows a revenue boost to $957 million, fueled by global generics. North American sales rose 17% year-over-year. 
Via Benzinga
News headline image
Dr. Reddy's Laboratories – Elliott Wave Technical Analysis ↗
Dr Reddy's Laboratories is progressing lower within a counter trend zigzag to terminate Minor Wave 4 Grey around 5600 levels. 
Via Talk Markets
News headline image
Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again? ↗
Dr. Reddy's Labs sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
News headline image
Organon Stock Sees Relative Strength Rating Rise To 91 ↗
On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before. 
Via Investor's Business Daily
News headline image
Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal ↗
Shanghai Multitude Therapeutics out-licensed global rights for its Tissue Factor ADC to Adcendo in a $1 billion agreement. The value of the agreement includes upfront and milestone payments, with... 
Via Talk Markets
News headline image
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold ↗
On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier. 
Via Investor's Business Daily
News headline image
Should Quality-Oriented Investors Explore DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)? ↗
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) can be considered a quality stock. Here's why. 
Via Chartmill
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.